Variation in Prescriber Responses to Drug Safety Alert Messages: Disease, Symptom, or Red Herring?

por Ollendorf, Daniel A.
Publicado 2010

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

por Gilbert, Thomas D, Smith, Daniel, Ollendorf, Daniel A
Publicado 2004

Patient and Caregiver Views on Measures of the Value of Health Interventions

por Voehler, Dominic, Neumann, Peter J, Ollendorf, Daniel A
Publicado 2022

The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition

por Ollendorf, Daniel A., Kim, Eunice, Bridger, Naomi, Naci, Huseyin
Publicado 2020

Frequency, Predictors, and Economic Impact of Upward Dose Adjustment of Infliximab in Managed Care Patients With Rheumatoid Arthritis

por Ollendorf, Daniel A., Massarotti, Elena, Birbara, Charles, Burgess, Somali Misra
Publicado 2005

The impact of external reference pricing on pharmaceutical costs and market dynamics

por Voehler, Dominic, Koethe, Benjamin C., Synnott, Patricia G., Ollendorf, Daniel A.
Publicado 2023

Bridging the gap: aligning economic research with disease burden

por Do, Lauren A, Synnott, Patricia G, Ma, Siyu, Ollendorf, Daniel A
Publicado 2021

Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries

por Ma, Siyu, Lavelle, Tara A., Ollendorf, Daniel A., Lin, Pei-Jung
Publicado 2022

Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates

por Breslau, Rachel Milstein, Cohen, Joshua T., Ollendorf, Daniel A., Neumann, Peter J.
Publicado 2022

Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis

por Bloudek, Lisa M, Pandey, Rajshree, Fazioli, Katherine, Ollendorf, Daniel A, Carlson, Josh J
Publicado 2021

Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma: A summary from the Institute for Clin...

por Beinfeld, Molly, Lee, Sei, McQueen, Brett, Fluetsch, Noemi, Pearson, Steven D, Ollendorf, Daniel A
Publicado 2021

The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis: A summary from the Institute for Clinical and Economic Review’s California Tech...

por Pandey, Rajshree, Ollendorf, Daniel A, Fazioli, Katherine, Bloudek, Lisa, Carlson, Josh J, Pearson, Steven D
Publicado 2021

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Mid...

por Synnott, Patricia G., McQueen, R. Brett, Ollendorf, Daniel A., Campbell, Jonathan D., Pearson, Steven D.
Publicado 2020

Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018

por Kim, David D., Silver, Madison C., Kunst, Natalia, Cohen, Joshua T., Ollendorf, Daniel A., Neumann, Peter J.
Publicado 2020

Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018

por Kim, David D., Silver, Madison C., Kunst, Natalia, Cohen, Joshua T., Ollendorf, Daniel A., Neumann, Peter J.
Publicado 2020

Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic

por Asukai, Yumi, Briggs, Andrew, Garrison, Louis P., Geisler, Benjamin P., Neumann, Peter J., Ollendorf, Daniel A.
Publicado 2021

Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions

por Chambers, James D, Enright, Daniel E, Panzer, Ari D, Cohen, Josh T, Ollendorf, Daniel A, Neumann, Peter J
Publicado 2023

Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending

por Kim, David D., Daly, Allan T., Koethe, Benjamin C., Fendrick, A. Mark, Ollendorf, Daniel A., Wong, John B., Neumann, Peter J.
Publicado 2022

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis

por Hendrix, Nathaniel, Ollendorf, Daniel A., Chapman, Richard H., Loos, Anne, Liu, Shanshan, Kumar, Varun, Linder, Jeffrey A., Pearson, Steven D., Veenstra, David L.
Publicado 2018

The Authors Respond

por Carlson, Josh J., Guzauskas, Gregory F., Chapman, Richard H., Synnott, Patricia G., Liu, Shanshan, Russo, Elizabeth T., Pearson, Steven D., Brouwer, Elizabeth D., Ollendorf, Daniel A.
Publicado 2018